...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Liver Failure Patients Caused by Hepatitis B: Short-Term and Long-Term Outcomes
【24h】

Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Liver Failure Patients Caused by Hepatitis B: Short-Term and Long-Term Outcomes

机译：乙型肝炎引起的肝衰竭患者的自体骨髓间充质干细胞移植：短期和长期结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Our study aimed to investigate the short-term efficacy and long-term prognosis of liver failure patients caused by hepatitis B after a single transplantation with autologous marrow mesenchymal stem cells (MMSCs). A total of 527 inpatients with liver failure caused by hepatitis B were recruited and received the same medical treatments, among whom 53 patients underwent a single transplantation with autologous MMSCs. A total of 105 patients matched for age, sex, and biochemical indexes, including alanine aminotransferase (ALT), albumin, total bilirubin (TBIL), prothrombin time (PT), and Model for End-Stage Liver Disease (MELD), comprised the control group. A total of 120 mL of bone marrow was obtained from each patient and then diluted and separated. Then, the MMSC suspension was slowly transfused into the liver through the proper hepatic artery. The success rate of transplantation was 100%, without serious side effects or complications. Levels of ALB, TBIL, and PT and MELD score of patients in the transplantation group were markedly improved from 2-3 weeks after transplantation, compared with those in the control group. At 192 weeks of follow-up, there were no dramatic differences in incidence of hepatocellular carcinoma (HCC) or mortality between the two groups. Additionally, there were no significant differences in the incidence of HCC or mortality between patients with and without cirrhosis in the transplantation group. Conclusion: Autologous MMSC transplantation is safe for liver failure patients caused by chronic hepatitis B. Short-term efficacy was favorable, but long-term outcomes were not markedly improved. In respect to several parameters, this method is preferable for patients with liver cirrhosis and may have potential for reducing their incidence of HCC and mortality.
机译：我们的研究旨在研究自体骨髓间充质干细胞（MMSCs）单次移植后由乙型肝炎引起的肝衰竭患者的短期疗效和长期预后。总共招募了527名由乙型肝炎引起的肝衰竭的住院患者，并接受了相同的治疗，其中53例接受了自体MMSC的单次移植。共有105例患者符合年龄，性别和生化指标，包括丙氨酸转氨酶（ALT），白蛋白，总胆红素（TBIL），凝血酶原时间（PT）和终末期肝病模型（MELD）。控制组。从每位患者中获得总计120毫升的骨髓，然后稀释并分离。然后，通过适当的肝动脉将MMSC悬浮液缓慢输注到肝脏中。移植成功率为100％，无严重副作用或并发症。移植后2-3周，移植组患者的ALB，TBIL，PT和MELD评分明显高于对照组。在192周的随访中，两组之间的肝细胞癌（HCC）发生率或死亡率没有显着差异。此外，移植组中有或没有肝硬化的患者之间的肝癌发生率或死亡率无显着差异。结论：自体MMSC移植对于慢性乙型肝炎所致肝衰竭患者是安全的。短期疗效较好，但远期疗效未见明显改善。就几个参数而言，该方法对肝硬化患者更可取，并且可能具有降低其HCC发生率和死亡率的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号